{"schema_version":"secwatch.filing_event.v1","accession":"0001156039-26-000039","form_type":"8-K","ticker":"ELV","cik":"0001156039","company_name":"Elevance Health, Inc.","filed_at":"2026-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.010694+00:00","generated_at":"2026-05-15T04:50:12.421111+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Elevance Health Q1 adj EPS $12.58 beats; raises FY2026 adj EPS guidance to at least $26.75","bullets":["Q1 operating revenue $49.5B (+1.5% YoY); diluted EPS $8.00, adjusted diluted EPS $12.58 (includes ~$1 non-recurring investment income).","Health Benefits segment revenue $42.5B (+2.6% YoY); operating margin 5.1% vs 5.4% YoY.","Carelon segment revenue $18.0B (+7.9% YoY); operating margin 5.9% vs 6.6% YoY.","Recorded $935M accrual for CMS matter and $129M business optimization charge; adjusted operating margin 6.5%.","FY2026 adjusted EPS guidance raised to at least $26.75; reaffirm operating cash flow at least $5.5B."],"urls":{"canonical":"https://secwatch.observer/filing/0001156039-26-000039","json":"https://secwatch.observer/filing/0001156039-26-000039.json","markdown":"https://secwatch.observer/filing/0001156039-26-000039.md","text":"https://secwatch.observer/filing/0001156039-26-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1156039/000115603926000039/0001156039-26-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1156039/000115603926000039/elv-20260422.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:50:12.421111+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"71a8c29c87e6e352cd1c4ac74e372c792747d360","claim":"Elevance Health, Inc. reported FY 2026 results: EPS at least $26.75. Guidance raised.","evidence_excerpt":"FY 2026 adjusted diluted EPS 2 guidance raised to at least $26.75, supported by underlying business strength, actions to reduce medical costs, and increased visibility","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1156039/000115603926000039/0001156039-26-000039-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"FY 2026"},{"label":"EPS","value":"at least $26.75"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"dad8c1146b5704ef6cb51c90e6b1bc0dc02720dd","claim":"Elevance Health, Inc. reported first quarter 2026 results: revenue $49.5 billion, EPS $8.00. Guidance raised.","evidence_excerpt":"ELEVANCE HEALTH REPORTS FIRST QUARTER 2026 RESULTS; RAISES FULL-YEAR GUIDANCE • 1Q 2026 operating revenue of $49.5 billion, up 1.5% from 1Q 2025 • 1Q 2026 diluted EPS 1 of $8.00; adjusted diluted EPS 2 of $12.58 driven by strong operating results and ~$1 per share of non-recurring investment income","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1156039/000115603926000039/0001156039-26-000039-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2026"},{"label":"Revenue","value":"$49.5 billion"},{"label":"EPS","value":"$8.00"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}